TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8501990

Group type: EXPERIMENTAL
Intervention: Cancer Rehabilitation Evaluation System (CARES) Psychosocial Summary Scale
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status score
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 227
Study: 2960861

Group type: EXPERIMENTAL
Intervention: Etretin (0, 25, or 50 mg/day for 8 weeks, followed by 25, 50, or 75 mg/day for optimal response)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Etretin
Number of subjects: 8
Study: 30206079

Group type: EXPERIMENTAL
Intervention: Advice, exercises and soft-tissue treatment plus manipulative therapy
Number of subjects: 238

Group type: COMPARATOR
Intervention: Advice, exercises and soft-tissue treatment
Number of subjects: 238
Study: 27257748

Group type: EXPERIMENTAL
Intervention: Formulation letters that paid attention to the development of AN
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: More reflective and respectful letters
Number of subjects: 46
Study: 24292991

Group type: EXPERIMENTAL
Intervention: Clarithromycin (1 g intravenously once daily for 4 days)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 21295363

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg/day and Ramipril 10mg/day
Number of subjects: 40
Study: 20394631

Group type: COMPARATOR
Intervention: C/BPO alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: C/BPO + PDL treatment (wavelength 585 nm, energy fluence 3 J cm(‐2), pulse duration 0.35 ms, spot size 7 mm)
Number of subjects: 80
Study: 18546664

Group type: EXPERIMENTAL
Intervention: Person-present scene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Person-absent scene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender discrimination task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faces in the scene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Object being fixated by the person in the scene
Number of subjects: 0
Study: 16484109

Group type: EXPERIMENTAL
Intervention: Method of loci
Number of subjects: 0

Group type: COMPARATOR
Intervention: Link method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rehearsal method
Number of subjects: 0
Study: 12100223

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg oral
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ergotamine 0.25 mg i.v.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg oral + ergotamine 0.25 mg i.v.
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 10543758

Group type: EXPERIMENTAL
Intervention: Clarithromycin-based regimens
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Clarithromycin-metronidazole regimen with omeprazole
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Clarithromycin-based regimen
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Susceptibility testing
Number of subjects: 516
Study: 7872936

Group type: EXPERIMENTAL
Intervention: Chronic low back pain patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 2171383

Group type: EXPERIMENTAL
Intervention: DBS3,3 at 50 mA
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DBS3,2 at 50 mA
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DBS3,3 and DBS3,2 at 20 and 30 mA
Number of subjects: 22
Study: 318951

Group type: EXPERIMENTAL
Intervention: Pentazocine 25 mg and Aspirin 325 mg (PA-L)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg and Aspirin 650 mg (PA-H)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 650 mg of Aspirin (A650)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 98
Study: 30084873

Group type: EXPERIMENTAL
Intervention: Bayesian approach to Mendelian randomization with multiple pleiotropic variants
Number of subjects: 0
Study: 30979460

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus with reduced-dose corticosteroids
Number of subjects: 150

Group type: COMPARATOR
Intervention: Prolonged-release tacrolimus with standard-dose corticosteroids
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus
Number of subjects: 150
Study: 28166457

Group type: EXPERIMENTAL
Intervention: Drug (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25950588

Group type: EXPERIMENTAL
Intervention: Mortality salience task
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cannabis smoking
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 92
Study: 23506415

Group type: EXPERIMENTAL
Intervention: Early surgical intervention (pancreaticojejunostomy or Frey-procedure)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Optimal current step-up practice (medical treatment followed by endoscopic interventions and surgery if needed)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Optimal current step-up practice
Number of subjects: 88
Study: 21621580

Group type: EXPERIMENTAL
Intervention: Tooth Mousse (TM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tooth Mousse plus 900 ppm F (TMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinpro with 950 ppm F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 ppm F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5000 ppm F
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19508745

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for MRKH (CBT-MRKH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16950026

Group type: EXPERIMENTAL
Intervention: Navigation-assisted less invasive total knee arthroplasty (LIS TKA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty (TKA)
Number of subjects: 102
Study: 15477790

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day) for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no citalopram)
Number of subjects: 28
Study: 11316109

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10789664

Group type: EXPERIMENTAL
Intervention: Doxazosin (2 to 8 mg/d)
Number of subjects: 24335

Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 to 25 mg/d)
Number of subjects: 24335
Study: 8795678

Group type: EXPERIMENTAL
Intervention: Salbutamol (nebulised)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air (Fio2 0.21)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxygen (Fio2 1.0)
Number of subjects: 12
Study: 1639990

Group type: EXPERIMENTAL
Intervention: Zona drilling (assisted hatching) in Trial 1
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Selective zona drilling in Trial 2
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group in Trial 1
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group in Trial 2
Number of subjects: 330
Study: 6236286

Group type: EXPERIMENTAL
Intervention: Sulpiride (as sole antidopaminergic therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30282181

Group type: EXPERIMENTAL
Intervention: Nasal vestibule flap group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Labial gingival crevicular approach group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 26489704

Group type: COMPARATOR
Intervention: DMARD group (placebo adalimumab)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DMARD+adalimumab group (adalimumab 40 mg/every other week)
Number of subjects: 180
Study: 24964689

Group type: EXPERIMENTAL
Intervention: Self-management improvement program based on social cognitive theory (SCT), lasting 12 weeks, consisting of 1.5 hours meeting once a week, including group meetings and home visit monitoring.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 44
Study: 22918099

Group type: EXPERIMENTAL
Intervention: Brush Buddies musical toothbrush
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colgate Smile toothbrush
Number of subjects: 120
Study: 19841966

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg initially, then two 5 mg/kg doses 24 h apart)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 51
Study: 17607190

Group type: EXPERIMENTAL
Intervention: Natalizumab (Tysabri)
Number of subjects: 0
Study: 16185378

Group type: EXPERIMENTAL
Intervention: Risperidone (average final dose 1.6 mg/day)
Number of subjects: 3909
Study: 12195170

Group type: EXPERIMENTAL
Intervention: Peak Clipping (PC) hearing aid circuit
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Compression Limiting (CL) hearing aid circuit
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Wide Dynamic Range Compression (WDRC) hearing aid circuit
Number of subjects: 360

Group type: COMPARATOR
Intervention: Unaided condition
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Aided condition
Number of subjects: 360
Study: 9442171

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 14
Study: 8596125

Group type: EXPERIMENTAL
Intervention: 300 ng/ml exogenous Plasmodium falciparum antigens
Number of subjects: 122

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 122

Group type: COMPARATOR
Intervention: Patients with P. falciparum malaria after 4 weeks of chemotherapy
Number of subjects: 122
Study: 2198931

Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30496493

Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (AET, continuous running)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: High-intensive interval training (IT, 4×4 method)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Resistance training (RT, circle training on 8 devices)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control condition (no change in lifestyle)
Number of subjects: 124
Study: 29368636

Group type: EXPERIMENTAL
Intervention: Electroacupuncture with usual care (EA with UC)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 108
Study: 26824942

Group type: EXPERIMENTAL
Intervention: Ganciclovir-Valganciclovir dosing adjusted based on Bayesian prediction model (group B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ganciclovir-Valganciclovir according to manufacturer's recommendations (group A)
Number of subjects: 53
Study: 24473153

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg administered 2 hours before surgery and then every 12 hours for 2 doses
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (identical capsule with same dosage)
Number of subjects: 56
Study: 21998121

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 18783877

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 376

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 376

Group type: COMPARATOR
Intervention: Androgen deprivation in watchful waiting group
Number of subjects: 376
Study: 18627504

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.9% normal saline (n = 38)
Number of subjects: 75
Study: 15991263

Group type: EXPERIMENTAL
Intervention: Guidelines plus ATP (Atepadene, 90 mg daily for 30 days)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Guidelines alone (no ATP)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Guidelines plus ATP
Number of subjects: 157
Study: 12106616

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 5799

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5799
Study: 10504011

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 34
Study: 8938674

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (lisinopril or enalapril)
Number of subjects: 52
Study: 1654706

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 13
Study: 6961459

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.56 g/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.94 g/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ethanol (both dosages)
Number of subjects: 30
Study: 30690930

Group type: EXPERIMENTAL
Intervention: FOLFIRI/aflibercept
Number of subjects: 78
Study: 27696520

Group type: EXPERIMENTAL
Intervention: Artificial pancreas system
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 32
Study: 26486986

Group type: EXPERIMENTAL
Intervention: VMAT (Volumetric Modulated Arc Therapy)
Number of subjects: 188

Group type: COMPARATOR
Intervention: 3DCRT (3D Conformal Radiotherapy)
Number of subjects: 188
Study: 25632744

Group type: EXPERIMENTAL
Intervention: Zhibai Dihuang Pill (ZBDHP), 6 g each time, twice daily for 90 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group: Vitamin E (100 mg each time, twice per day) and ATP (40 mg each time, twice per day) for 90 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Zhibai Dihuang Pill (ZBDHP)
Number of subjects: 80
Study: 22189364

Group type: EXPERIMENTAL
Intervention: Pneumatic pulsation therapy (5 treatments over 2 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 50
Study: 20003782

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic calf compression (IPC)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight heparin (LMWH)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no prevention strategy)
Number of subjects: 143
Study: 17221296

Group type: EXPERIMENTAL
Intervention: Substance dependence (detoxification)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Heroin use
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Past suicide attempt
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Persistent homelessness
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Chronic medical illness
Number of subjects: 470

Group type: COMPARATOR
Intervention: Receipt of primary care
Number of subjects: 470
Study: 15045190

Group type: EXPERIMENTAL
Intervention: Bazoton uno (459 mg dry extract of stinging nettle roots)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Bazoton uno
Number of subjects: 246
Study: 11446046

Group type: EXPERIMENTAL
Intervention: Low-dose spiral CT scanning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-randomized population-based studies
Number of subjects: 0
Study: 9543646

Group type: EXPERIMENTAL
Intervention: Nicotine (two 22 mg transdermal patches)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7515168

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferons (in combination with chemotherapy and other immunological agents)
Number of subjects: 0
Study: 2660376

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31909672

Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Taste-matched placebo
Number of subjects: 32
Study: 29971868

Group type: EXPERIMENTAL
Intervention: STE in lead aVL
Number of subjects: 32

Group type: COMPARATOR
Intervention: No STE in lead aVL
Number of subjects: 32
Study: 27267893

Group type: EXPERIMENTAL
Intervention: Curcumin (3.6 g/day for 6 months)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 223
Study: 25428632

Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy and simultaneous talc poudrage (4g)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Seldinger chest drain insertion followed by instillation of sterile talc (4g)
Number of subjects: 330
Study: 23514638

Group type: EXPERIMENTAL
Intervention: LIA with ketorolac 30 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 20492044

Group type: EXPERIMENTAL
Intervention: Hegu-Sanyinjiao Matched Points
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Hegu
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Zusanli
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 134
Study: 18237581

Group type: EXPERIMENTAL
Intervention: Very-low-fat vegan diet supplemented with soy protein and lifestyle changes
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study: 15627853

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) followed by Well-being Therapy (WBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 20
Study: 12201354

Group type: EXPERIMENTAL
Intervention: Delapril 30 mg plus Indapamide 2.5 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Fosinopril 20 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 171
Study: 9989963

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study: 7775365

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 17
Study: 2156343

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens 0.625 mg for 21 days plus placebo during the last 10 days of each cycle
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens 0.625 mg for 21 days plus medrogestone 5 mg/d for 10 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7030636

Group type: EXPERIMENTAL
Intervention: 200 mg slow-release metoprolol once daily for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: 200 mg conventional metoprolol once daily for 6 weeks
Number of subjects: 50
Study: 31327421

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy for prostate cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conformal irradiation of the prostate
Number of subjects: 0
Study: 27398706

Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels in women who developed preeclampsia (3.52; 0.11-25.3)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Cell-free total DNA levels in controls (3.74; 0.12-21.14)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels in African American women (6.15; 0.14-28.73)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels in Hispanic women (4.95; 0.20-26.82)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels and maternal body mass index (BMI)
Number of subjects: 350
Study: 25575262

Group type: EXPERIMENTAL
Intervention: Synbiotic composition (5 days prior and 10 days after surgery)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 23716409

Group type: EXPERIMENTAL
Intervention: Fee-based As testing with household education (HE)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Fee-based As testing with household education and local media campaign (HELM)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Fee-based As testing alone (Control)
Number of subjects: 452
Study: 21838506

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the subthalamic nucleus (STN)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the globus pallidus internus (GPi)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Levodopa therapy postoperatively
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Externally scaled jaw velocity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Turning DBS off and on
Number of subjects: 27
Study: 19364964

Group type: EXPERIMENTAL
Intervention: Intensive dose-dense (IDD) chemotherapy
Number of subjects: 668

Group type: COMPARATOR
Intervention: Epirubicin/paclitaxel (control)
Number of subjects: 668
Study: 17587070

Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMOX) 1 g twice daily for 100 days
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups (AMOX and PBO)
Number of subjects: 145
Study: 15125804

Group type: EXPERIMENTAL
Intervention: Favourable social comparison information
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Lower personal risk
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Cardiac event vignettes
Number of subjects: 970

Group type: COMPARATOR
Intervention: Unfavourable social comparison information
Number of subjects: 970
Study: 11996472

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 every 3 weeks)
Number of subjects: 30
Study: 9882028

Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g daily
Number of subjects: 99
Study: 7526415

Group type: EXPERIMENTAL
Intervention: Biopsy group
Number of subjects: 170

Group type: COMPARATOR
Intervention: Nonbiopsy group
Number of subjects: 170

Group type: COMPARATOR
Intervention: Biopsy group vs Nonbiopsy group
Number of subjects: 170
Study: 2844641

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-tryptophan (5OHT) plus placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-tryptophan (5OHT) after dexamethasone pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: pizotifen (Piz)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 31743131

Group type: EXPERIMENTAL
Intervention: Low-risk HPV (lrHPV) RNA positive IPs
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-risk HPV (lrHPV) RNA negative IPs
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control nonkeratinizing SCCs
Number of subjects: 44